Previously known AD markers including Tau and amyloid-beta peptides have been identified across multiple mass-spectrometry-based proteomics studies and have been successfully developed into targeted assays for quantitation [44,45,46,47]. The gene discussed is MAPT; the disease is Alzheimer disease.